NIH analysis finds,
"after age 53, the model suggests that there is no predicted
benefit to receiving immunomodulatory DMTs for the average MS patient."
https://www.ncbi.nlm.nih.gov/pmc/art...r-08-00577.pdf
"after age 53, the model suggests that there is no predicted
benefit to receiving immunomodulatory DMTs for the average MS patient."
https://www.ncbi.nlm.nih.gov/pmc/art...r-08-00577.pdf
Comment